APA (7th ed.) Citation

B, A., JM, L., & P, L. (2024). Nirsevimab to reduce infant morbidity from respiratory syncytial virus. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 196(32), E1114. https://doi.org/10.1503/cmaj.240780

Chicago Style (17th ed.) Citation

B, Abu-Raya, Langley JM, and Lavoie P. "Nirsevimab to Reduce Infant Morbidity from Respiratory Syncytial Virus." CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne 196, no. 32 (2024): E1114. https://doi.org/10.1503/cmaj.240780.

MLA (9th ed.) Citation

B, Abu-Raya, et al. "Nirsevimab to Reduce Infant Morbidity from Respiratory Syncytial Virus." CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne, vol. 196, no. 32, 2024, p. E1114, https://doi.org/10.1503/cmaj.240780.